Apricus Biosciences Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Mirror Image

5/9/2016 11:53:18 AM

of 2026

Given the information in the 10Q - it doesn't seem that Vitaros is available in Germany, Sweden or Belgium at this time.
Also - the 10Q provides information to which territories are experiencing better Vitaros Sales.

Seems like France would be the most successful market ( double in royalties from the second successful market ), followed by Italy, then Spain, the U.K. and finally Belgium & Sweden ( partially for the quarter ).

Hexal / Sandoz 2015 1Q numbers have $350K from the expanded agreement between them and Apricus. So - royalties would be around $60K for the quarter.

Takeda's royalties did in fact decrease for the same period. My guess is that they were using less resources to promote Vitaros in their territory. They were probably winding down because they were looking to get out of that market ( as they did in April ).

2016 (1)

2015

Ferring International Center S.A. ("Ferring")

$

—

$

—

Hexal AG, an affiliate within the Sandoz Division of the Novartis Group of Companies ("Sandoz")

11

410

Takeda Pharmaceuticals International GmbH (“Takeda”)

39

65

Laboratories Majorelle ("Majorelle")

174

—

Recordati Ireland Ltd. ("Recordati")

63

—

Bracco SpA (“Bracco”)

84

—

$

371

$

475

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next